Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 3Recurrence 3Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Multiple Myeloma 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Lymphoma, T-Cell, Peripheral 1Liposarcoma 1Inhibition of Autophagy Synergizes Anti-tumor Effect 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Genetic Diseases, Inborn 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1

Interventions

Cyclophosphamide 37fludarabine phosphate 27Peripheral Blood Stem Cell Transplantation 24Whole-Body Irradiation 18Etoposide 18Doxorubicin 17Vincristine 16Mycophenolic Acid 16Cyclosporine 16Prednisone 15Tacrolimus 12Busulfan 12Bortezomib 12Methotrexate 11Antilymphocyte Serum 11Rituximab 10Melphalan 10Gemcitabine 9Carboplatin 9Lenalidomide 8Filgrastim 8Vorinostat 7Radiotherapy 7Everolimus 7Alemtuzumab 6romidepsin 5Methylprednisolone 5Ifosfamide 5Flow Cytometry 5Cytarabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Immunoblastic Lymphadenopathy × Clinical Trials, Phase II as Topic × Clear all
NCT02223208 2025-12-02

FIL_PTCL13

Fondazione Italiana Linfomi - ETS

Phase 1/2 Active not recruiting
89 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡